title: [Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study].
abstract: OBJECTIVE
  To compare patient preference for sildenafil citrate (sildenafil) vs. tadalafil and for their respective dosing instructions in a cohort of Spanish patients with erectile dysfunction (ED).
  
  
  METHODS
  Sixty four Spanish patients from a multicenter, two period, cross-over, double-blind study (265 patients enrolled in total) were randomized to receive on-demand sildenafil 50 mg or tadalafil 20 mg for 12 weeks and afterwards were crossed over to the alternate regimen for another 12 weeks to assess drug preference in an extension period of the study. Similarly, to evaluate preference for their respective dosing instructions, 30 patients were randomized to one of the 2 arms treated with tadalafil: one with sildenafil (S) dosing instructions and the other with tadalafil (T) dosing instructions.
  
  
  RESULTS
  Seventy percent of 56 patients completing the study chose to receive tadalafil treatment versus sildenafil treatment (30%) in the extension period (p<0.01). Correspondingly, 73% of 13 evaluating each drug dosing instructions preferred T dosing instructions (p>0.05). Preference did not vary with age, concomitant diseases and previous use of sildenafil.
  
  
  CONCLUSIONS
  In this study, 7 out of 10 patients preferred tadalafil and its dosing instructions to sildenafil, for the treatment of their ED.
authors.affiliation: Hospital Miguel Servet, Zaragoza.
authors.forename: L
authors.initials: L
authors.lastname: Rodríguez Vela
authors.forename: E
authors.initials: E
authors.lastname: Lledó García
authors.forename: O
authors.initials: O
authors.lastname: Rajmil
authors.forename: D
authors.initials: D
authors.lastname: Mo
authors.forename: A
authors.initials: A
authors.lastname: Cassinello
authors.forename: J
authors.initials: J
authors.lastname: Casariego
mesh_terms: D000328:Adult; D000368:Aged; D002243:Carbolines / Q000627:therapeutic use*; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005060:Europe; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D000068581:Tadalafil; D014481:United States
chemical_list: D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068581:Tadalafil; D000068677:Sildenafil Citrate